RxDoctor Payments Data

Arthur Kopp, MD

Psychiatry · Culver City, CANPI 1598977241

Payments from drug & device makers

$8,414in general payments, 2019–2025

Across 193 payments — averaging $43.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$5K
  • Teva Pharmaceuticals USA, Inc.$929
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$848
  • Johnson & Johnson$500
  • Sunovion Pharmaceuticals Inc.$443
  • Otsuka America Pharmaceutical, Inc.$379
  • plus $591 from 6 others
$1,281in research payments, 2019–2025

Across 7 payments — averaging $182.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K

What the payments were for

  • Travel & lodging$3,03836%
  • Food & beverage$5,01660%
  • Education$3604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,414 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$14,873
Medicare patients
18
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$32,702
FanaptIloperidone12$27,985
Aripiprazole84$13,963
Fluphenazine Hcl12$8,095
Clozapine26$5,682
Haloperidol42$2,189
Divalproex Sodium29$1,256
Divalproex Sodium ErDivalproex Sodium29$1,054
Risperidone33$893
Benztropine Mesylate39$683
Lorazepam40$370
Olanzapine28$312
Gabapentin18$284
Quetiapine Fumarate24$276
Sertraline Hcl42$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$500$32,70213 claims
Vanda Pharmaceuticals Inc.Fanapt$18$27,98512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →